0
mg/
kg/
day
30
mg/
kg/
day
75
mg/
kg/
day
160
mg/
kg/
day
Urinary
System
Kidney
(
50)
(
50)
(
48)
(
50)
Atrophy,
focal
4
(
8%)
4
(
8%)
Autolysis
1
(
2%)
Casts
1
(
2%)
Congestion
1
(
2%)
Crystals
1
(
2%)
21(
42%)
Cyst
3
(
6%)
1
(
2%)
4
(
8%)
2(
4%)
Glomerulosclemsis
1
(
2%)
Inflammation,
acute,
focal
1
(
2%)
Inflammation,
chronic
1(
2%)
Mineralization
28
(
56%)
33
(
66%)
32
(
67%)
36(
72%)
Nephropathy
1
(
2%)
2
(
4%)
19(
38%)
Cortex,
cyst
1
(
2%)
Renal
tubule,
cyst
1
(
2%)
Renal
tubule,
degeneration
1
(
2%)
1
(
2%)
Renal
tubule,
dilatation
1
(
2%)
2
(
4%)
Renal
tubule,
mineralization
1
(
2%)

23
(
46%)
Renal
tubule,
regeneration
25
(
50%)
28
(
58%)
21(
42%)

Urinary
bladder
(
49)
(
49)
(
45)
(
45)
Inflammation,
granulomatous
1
(
2%)

0
mg/
kg/
day
40
mg/
kg/
day
90
mg/
kg/
day
200
mg/
kg/
day
Urinary
System
Kidney
(
50)
(
53)
(
50)
(
54)

Amyloid
deposition
2
(
4%)
Atrophy,
focal
2(
4%)
2
(
4%)
4
(
8%)
1
(
2%)
Casts
1
(
2%)
Congestion
1
(
2%)
1
(
2%)
Crystals
36
(
67%)
Glomerulosclerosis
1(
2%)
1
(
2%)
Hyperplasia,
lymphoid
1
(
2%)
Inflammation,
focal
1(
2%)
Metaplasia,
osseous
1
(
2%)
Mineralization
3(
6%)
1
(
2%)
2
(
4%)
Nephropathy
2
(
4%)
I
(
2%)
37
(
69%)
Papilla,
necrosis
I
(
2%)
Renal
tubule,
degeneration
2
(
4%)
Renal
tubule,
dilatation
2
(
4%)
1
(
2%)
2
(
4%)
Renal
tubule,
pigmentation,
hemosiderin
1
(
2%)
Renal
tubule,
regeneration
5(
10%)
6
(
11%)
9
(
18%)
2
(
4%)
Urinary
bladder
(
47)
(
46)
(
46)
(
48)
Hyperplasia,
lymphoid
1
(
2%)
Inflammation,
chronic,
focal
2
(
4%)
Data
from
NTP
Technical
Report
432
Appendices
C
and
D
from
which
EPA's
draft
RfD
is
derived.

Non­
Neoplastic
Lesions
in
Male
mice
Non­
Neoplastic
Lesions
in
Female
mice
